Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
Avanos Medical Inc — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that, after an internal realignment, it holds 0 shares of Avanos common stock, equal to 0% of the class. The amendment explains certain Vanguard subsidiaries now report beneficial ownership separately following an internal realignment on January 12, 2026.
Hurley John Joseph reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical, Inc. reported that Principal Accounting Officer John Joseph Hurley received an award of 2,211 time-based restricted share units under the company’s 2021 Long Term Incentive Plan. These units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, and each unit is economically equivalent to one share of common stock. Following this compensation grant, his reported direct holdings increased to 13,592 shares or share-equivalents.
Avanos Medical SVP and CFO Scott Michael Galovan reported equity awards as part of his compensation. He received an employee stock option grant for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
He was also granted 29,481 time-based restricted share units, each economically equivalent to one share of Common Stock. These RSUs vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029. Following the grants, he holds 139,824 shares of Common Stock directly and 96,212 options.
Avanos Medical, Inc. reported that Chief Executive Officer David Pacitti received new equity awards. He was granted employee stock options for 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
Pacitti also received 101,341 time-based restricted share units under the 2021 Long Term Incentive Plan. These restricted units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, and each unit is the economic equivalent of one share of Common Stock. Following these grants, he holds 343,388 shares of Common Stock directly.
Avanos Medical SVP Sigfrido Delgado received new equity awards as part of compensation. On March 13, 2026, he was granted employee stock options for 37,520 shares of Common Stock at an exercise price of $13.69 per share, expiring March 13, 2036. These options vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029. He was also awarded 15,886 time-based restricted share units, each economically equivalent to one share of Common Stock, vesting one-third on March 13, 2027, one-third on March 13, 2028 and one-third on March 13, 2029. Following these awards, Delgado directly holds 60,005 shares of Common Stock and 59,434 derivative securities.
Avanos Medical, Inc. reported a change to its executive compensation program. Effective beginning in 2026, the Board of Directors increased the target value of the annual long-term incentive grant for Chief Executive Officer David C. Pacitti under the 2021 Long Term Incentive Plan from $5,000,000 to $5,500,000. This adjustment affects the equity-based incentive opportunity for the CEO and does not change reported financial results.
Avanos Medical, Inc. is seeking stockholder approval at its 2026 annual meeting to elect eight directors, ratify Deloitte & Touche LLP as auditor, approve executive compensation on an advisory basis, and amend the 2021 Long Term Incentive Plan so outside directors can receive equity awards without increasing shares reserved.
The meeting will be held on April 21, 2026 at company headquarters in Alpharetta, Georgia, for stockholders of record as of February 20, 2026, when 46,507,755 common shares were outstanding. The company highlights strong governance, inclusive culture, and significant 2025 sustainability gains, including lower greenhouse gas emissions, waste, and water use.
Avanos Medical, Inc. Principal Accounting Officer John Joseph Hurley reported a small tax-related share disposition. On March 9, 2026, 226 shares of common stock were surrendered at $13.29 per share to cover tax withholding when 647 time-based restricted share units vested. After this tax-withholding disposition, Hurley directly holds 11,381 shares of Avanos common stock.
AVANOS MEDICAL, INC. Senior Vice President and Chief Financial Officer Scott Michael Galovan reported a routine tax-related share disposition. On March 9, 2026, 1,119 shares of common stock were surrendered to the company to satisfy tax withholding obligations tied to the vesting of 3,235 time-based restricted share units, each equivalent to one share of common stock. After this tax-withholding transaction, he directly holds 110,343 shares of common stock.